Serum interleukin 1 in ovarian cancer patients

European Journal of Cancer

Volumn 34, Issue 6, 1998, Pages 931-933

  Zeisler, H ^a   Tempfer, C ^a   Joura, E A ^a   Sliutz, G ^a   Koelbl, H ^a   Wagner, O ^a   Kainz, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Interleukin 1; Ovarian cancer; Serum level

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; OVARY CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0032078927     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10107-1     Document Type: Letter

References (14)

1. Taylor KJW, Schwarte PE. Screening for early ovarian cancer. Radiology 1994, 192, 1-10.
2. Herbst AL. The epidemiology of ovarian carcinoma and the current status of tumour markers to detect disease. Am J Obstet Gynecol 1994, 170, 1099-1105.
3. Kutteh WH, Doellgast GJ. Autologous antibodies eluded from membrane fragments in human ovarian epithelial neoplastic effusions. II. Tissue specificity and reactivity. J Natl Cancer Inst 1986,76,797-804.
4. Platanias LC, Vogelzang NJ. Interleukin: biology, pathophysiology and clinical prospects. AmJMed 1990, 89, 621-629.
5. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Interleukin-1 as a cytocidal factor for several tumour cell lines. J Immunol 1985, 135, 3962-3968.
6. Lachman LB, Dinarello CA, Llanska ND, Filder IJ. Natural and recombinant human interleukin-lB is cytotoxic for human melanoma cells. J Immunol 1986, 136, 3098-3103.
7. Braunschweiger PG, Johnson CS, Kumar W, Ord V, Furmanski P. Antitumor effects of recombinant interleukin-1 alpha in RIF-1 and Pane O2 solid tumours. Cancer Res 1989, 48, 6011-6016.
8. Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer 1992, 70, 709-713.
9. Kabir S, Grant C, Daar AS. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett 1995, 95, 207-212.
10. Moradi MM, Carson LF, Weiberg B, Haney AF, Twiggs LB, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993, 72, 2433-2440.
11. Punnonen J, Heinonen PK, Kuoppala T, Jansen CT, Punnonen R. Production of interleukin-1 β and tumour necrosis factor-α in patients with benign or malignant ovarian tumours. J Cancer Res Clin Oncol 1991, 117, 587-592.
12. Li BY, Mohanraj D, Olson MC, et al. Human ovarian epithelial cancer cells cultured in vitro express both interleukin 1α and β genes. Cancer Res 1989, 51, 4476-4480.
13. Haskill S, Becker S, Fowler W, Walton L. Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material. Br J Cancer 1982, 45, 728-735.
14. Erroi S, Sironi M, Chiaffarino F, Chen ZG, Mengozi M, Mantovani M. IL-1 and IL-6 release by tumour-associated macrophages from human ovarian carcinoma. Int J Cancer 1989, 44, 795-801.